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Abstract 27 
M/XDR-TB has become an increasing threat in high burden countries but also in affluent regions due 28 
to increased international travel and globalization. Carbapenems are earmarked as potentially active 29 
drugs for the treatment of M. tuberculosis. To better understand the potential of carbapenems for 30 
the treatment of M/XDR-TB, the aim of this review was to evaluate the literature on currently 31 
available in vitro, in vivo and clinical data on carbapenems in the treatment of M. tuberculosis and 32 
detection of knowledge gaps, in order to target future research. 33 
In February 2018, a systematic literature search of PubMed and Web of Science was performed. 34 
Overall the results of the studies identified in this review, which used a variety of carbapenem 35 
susceptibility tests on clinical and lab strains of M. tuberculosis, are consistent. In vitro the activity of 36 
carbapenems against M. tuberculosis is increased when used in combination with clavulanate, a BLaC 37 
inhibitor. However, clavulanate is not commercially available alone, and therefore is it practically 38 
impossible to prescribe carbapenems in combination with clavulanate at this time. Few in vivo 39 
studies have been performed, one prospective, two observational and seven retrospective clinical 40 
studies to assess effectiveness, safety and tolerability of three different carbapenems (imipenem, 41 
meropenem and ertapenem). Presently we found no clear evidence to select one particular 42 
carbapenem among the different candidate compounds, to design an effective M/XDR-TB regimen. 43 
Therefore more clinical evidence and dose optimization substantiated by hollow fiber infection 44 
studies are needed to support repurposing carbapenems for the treatment of M/XDR-TB. 45 













Treatment of tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, has become more 48 
challenging with the emergence of multidrug resistant (MDR)-TB and extensively drug resistant 49 
(XDR)-TB among previously and newly detected cases (1). M/XDR-TB has become an increasing 50 
threat in high burden countries but also in affluent regions due to increased international travel and 51 
globalization.  52 
 53 
MDR-TB is defined as an infectious disease caused by M. tuberculosis that is resistant to at least 54 
isoniazid and rifampicin. XDR-TB is defined as MDR-TB with additional resistance to at least one of 55 
the fluoroquinolones and to at least one of the injectable second line drugs (amikacin, capreomycin 56 
or kanamycin). New TB drugs, with a novel mechanism of action, include bedaquiline and delamanid 57 
that have recently been approved and included in the World Health Organization guidelines on MDR-58 
TB as add-on agents (2). Unfortunately resistance to these agents has already been detected (3). 59 
Exploration of currently available drugs for their potential effect against TB, may be an additional 60 
source for potential candidates to be used in case of extensive resistance to try to compose a 61 
treatment regimen (4-5). 62 
 63 
Beta-lactam antimicrobial drugs are widely used drugs for the treatment of a range of infections. 64 
Also, imipenem-cilastatin and meropenem have been listed as add-on drugs in the updated WHO 65 
treatment guidelines (6). Carbapenem activity has long been considered to be of limited use, due to 66 
rapid hydrolysis of the beta -lactam ring by broad-spectrum mycobacterial class A beta-lactamases 67 
(BLaC). The addition of the BLaC inhibitor clavulanate suggests that beta-lactams combined with 68 
BLaC inhibitors could be beneficial in the treatment of TB (7). Recent studies suggest that beta-69 













The bacterial activity of beta-lactams is due to the inactivation of bacterial transpeptidases, 72 
commonly known as penicillin binding proteins (PBP), which inhibit the biosynthesis of the 73 
peptidoglycan layer of the cell wall of bacteria (8,15). Polymerizations of the peptidoglycan layer in 74 
most bacteria are predominantly cross-linked by D,D-transpeptidases (DDT), the enzymes inhibited 75 
by beta-lactams (8,16). The majority of crosslinks in peptidoglycan appear to be formed by the non-76 
classical L,D-transpeptidases (LDT) in M. tuberculosis (17-23). Several studies revealed the structural 77 
basis and the inactivation mechanism of LDT and the active role of carbapenems, providing a basis 78 
for the potential use of carbapenems in inhibiting M. tuberculosis (24-28).  79 
 80 
Beta-lactams show time-dependent activity, carbapenems have been shown to have bactericidal 81 
activity when the free drug plasma concentration exceeds the MIC for at least 40 % of the time in 82 
non-TB bacterial species (29-30). 83 
 84 
Carbapenems are earmarked as potentially active drugs for the treatment of M. tuberculosis. To 85 
better understand the potential of carbapenems for the treatment of M/XDR-TB, the aim of this 86 
review was to evaluate the literature on currently available in vitro, in vivo and clinical data on 87 
carbapenems in the treatment of M. tuberculosis and detection of knowledge gaps, in order to target 88 
future research. 89 














This systematic review was conducted in accordance with the Preferred Reporting Items for 93 
Systematic Reviews and Meta-Analyses (PRISMA) statement (31).  94 
 95 
Search 96 
In February 2018, a systematic literature search of PubMed and Web of Science, without restrictions 97 
with respect to publication date was employed using the key words (´Carbapenem’ OR 98 
‘Carbapenems’ OR ‘Imipenem’ OR ‘Meropenem’ OR ‘Ertapenem’ OR ‘Doripenem’ OR ‘Faropenem’ 99 
OR ‘Biapenem’ OR ‘Panipenem’ OR ‘Tebipenem’) AND (‘Tuberculosis’ OR TB OR Mycobacterium 100 
tuberculosis) as MeSh Terms. Retrieved studies and abstracts from both PubMed and Web of Science 101 
were pooled and duplicates were removed. Titles and abstracts of retrieved articles were screened. 102 
Reviews, case-reports or studies on other species than TB or studies on other drugs than 103 
carbapenems were excluded. Studies were screened for eligibility. If eligible, the full-text was read by 104 
a researcher (SvR). A second researcher (MZ) independently repeated the article search and 105 
selection. Discrepancies were resolved by discussion, or a third researcher was consulted (JWA). Full 106 
text papers were subdivided into three sections; in vitro, in vivo and clinical data. Full text papers for 107 
in vitro data were eligible for inclusion if an M. tuberculosis strain was studied and minimum 108 
inhibitory concentrations were reported. Full text papers for in vivo data were eligible for inclusion if 109 
treatment of M. tuberculosis infections with carbapenems were studied in animal models, and if 110 
colony forming units and/or survival data were reported. Full text papers for clinical data were 111 
eligible for inclusion if pharmacokinetics of carbapenems or safety or response to treatment 112 
measured as surrogate end points (sputum conversion) or clinical end points were studied and 113 
reported. References of all included articles were screened by hand. The same systematic search was 114 
performed using clinicaltrials.gov to find ongoing studies investigating carbapenems in TB patients 115 












Data extraction 117 
A researcher (SvR) performed data extraction first by using a structured data collection form. A 118 
second researcher (MZ) verified the data extraction independently. Data were subdivided into three 119 
sections; in vitro, in vivo and clinical data. Variables in the section ‘in vitro’ included; M. tuberculosis 120 
strain, experimental methods, drug of interest. Minimal inhibitory concentration, minimal inhibitory 121 
concentration with clavulanic acid, minimal bactericidal concentration and colony forming units 122 
(CFU) were extracted from the included articles. For the section ‘in vivo’ the following data were 123 
included; M. tuberculosis strain, mice, route of infection, drug of interest with or without clavulanic 124 
acid, dose, and treatment, colony forming units and survival rate, were retrieved from the included 125 
articles. For the clinical section, we extracted data from the included articles on type of study 126 
population, number of subjects, study design, drug of interest, and dosage. Sputum smear, sputum 127 
culture, treatment success, adverse events and interruption due to adverse events were noted as 128 
outcomes. AUC, Peak drug concentration (Cmax), half-life (t1/2), Distribution volume (Vd), and 129 
clearance were extracted. Possibility of pooling data from included data was assessed on data 130 
presentation. 131 
 132 
Data quality 133 
No validated tool for risk of bias assessment for in vitro studies, in vivo studies and pharmacokinetic 134 
studies was available. To be able to assess the quality of each study, we verified if each study 135 
reported on key-elements required for adequate data interpretation. If studies reported adequately 136 
on the key-elements, risk of bias was considered to be low. If studies had missing data or if 137 
procedures were not clear or not mentioned, risk of bias was considered to be high. The following 138 
key-elements were identified for in vitro studies; description of lab or clinical strains, minimal sample 139 
size of >10 strains, >3 concentrations tested per drug, MIC/CFU determined using the proportion 140 
method, evaluation endpoint of minimal inhibitory concentration (MIC 50 or MIC 90), evaluation of 141 












description of laboratory or clinical strains, type of mice, route of administration of the drug, dose 143 
and treatment duration, MIC/CFU determined using the proportion method, evaluation of endpoint 144 
of CFU and survival rate and for clinical studies; for human studies; study design,  patient population 145 
(TB/MDR-TB; HIV co-infection), number of study participants, endpoints tested, defined as sputum 146 
smear conversion, sputum culture conversion, treatment success, adverse events. The following 147 
components were checked for pharmacokinetic studies: sample size, type of patients, type of assay, 148 
number of plasma samples drawn per patient, sample handling, use of validated analytical methods 149 
and method of AUC calculation. 150 
 151 
Results 152 
Based on the selection criteria, 250 articles were retrieved in PubMed and 260 in Web of Science. 153 
After removal of 146 duplicates, 364 articles remained for screening. After screening of the title and 154 
abstract, 46 articles remained for full text evaluation. Reasons for exclusion included; not available 155 
(n=6), other drugs (n=2), no MIC (n=1), case-report (n=1), other (n=1). After this process, 35 relevant 156 
articles were included in this study (Flow chart; Fig 1). Due to low number and high diversity of 157 
strains, analytical methods and study designs, presence of biochemical instability of the drugs of 158 
interest, the short half-life of drugs of interest in mice and the diversity in MIC determination, we did 159 
not have enough data to perform a meta-analysis. Risk of bias of the included studies is shown in 160 
table S1.  Studies on clinicaltrials.gov are shown in S2. 161 
 162 
In vitro 163 
Results of the in vitro studies reporting on carbapenems are presented in table 1. 164 
 165 
Imipenem 166 
Susceptibility testing of imipenem, using various analytical methods against strain H37Rv, H37Ra, 167 












without clavulanic acid and a range of MIC’s between 0.16 – 32 with clavulanic acid. (8,32-37). When 169 
Imipenem was combined with clavulanate it showed a 4-16-fold lower MIC against the M. 170 
tuberculosis H37Rv reference strain (8,33-35).  171 
 172 
Meropenem 173 
Multiple studies reported that meropenem in presence of clavulanate is active in vitro against clinical 174 
and lab strains, H37Rv and H37Ra, of M. tuberculosis, showing MIC’s ≤ 1 mg/L. In vitro studies 175 
reporting susceptibility of meropenem of M. tuberculosis reference strain and clinical isolates 176 
showed MIC values between 1 - 32 mg/L (8,33-44). Meropenem in combination with clavulanic acid 177 
was shown to have a MIC between 0.063 – 32 mg/L  (33-35,38,43) Meropenem in combination with 178 
clavulanate killed the non-replicating ss18b strain of M. tuberculosis moderately and was shown to 179 
have a MIC of 0.125 – 2.56 mg/L against M. tuberculosis H37Rv strains (8,34-35,40).  A decrease of a 180 
2 log10 CFUs over six days was reported in M. tuberculosis-infected murine macrophages (40). 181 
 182 
Ertapenem 183 
In clinical strains of M. tuberculosis the MIC of ertapenem, as single agent, was 16 mg/L and when 184 
combined with clavulanate 4 mg/L (33,35). Another study showed ertapenem was unstable 185 
degrading faster than the doubling time of M. tuberculosis in the growth media used, suggesting 186 
previous published MICs of ertapenem are likely to be falsely high (45). In a hollow fiber model with 187 
supplementation of ertapenem in a broth microdilution test, ertapenem showed a MIC of 0.6 ml/L 188 
(46). A 28-day exposure-response hollow fiber model of TB study tested 8 different doses of 189 
ertapenem in combination with clavulanate and identified the ertapenem exposure associated with 190 
optimal sterilizing effect for clinical use. Monte Carlo simulation with 10,000 MDR-TB patients 191 
identified a susceptibility breakpoint MIC of 2 mg/L for an intravenous dose of 2 g once a day that 192 













Faropenem showed a 4-fold reduction when combined with clavulanic acid (33,34), resulting in a MIC 195 
range between 1 - 5 mg/L (33-34, 47-49) In a hollow fiber model, the optimal target exposure was 196 
identified to be associated with optimal efficacy in children with disseminated TB using Monte Carlo 197 
simulations; the predicted optimal oral dose was 30 mg/kg of Faropenem/medoximil 3-4 times daily. 198 
The exposure target for Faropenem/medoximil was 60% Tfree>MIC (50).   199 
 200 
Other carbapenems 201 
Other carbapenems, such as doripenem, biapenem and tebipenem showed at least a  2-fold 202 
reduction in MIC when combined with clavulanic acid (33,37,43,51).  203 
 204 
In vivo 205 
Results of the in vivo studies reporting on carbapenems are presented in table 2. 206 
 207 
Imipenem 208 
The bacterial burden in imipenem-treated CD-1 female mice (twice daily (BID) 100 mg/kg), infected 209 
with M. tuberculosis strain H37Rv, was reduced by 1.8 log10 in splenic tissue and 1.2 log10 in lung 210 
tissue after 28 days, showing an anti-mycobacterial effect as well as improved survival in this mouse 211 
model (52). In another study Swiss mice, infected with M. tuberculosis strain H37Rv, were treated 212 
with a subcutaneous administration of 100-mg/kg imipenem in combination with clavulanate once a 213 
day to simulate a human equivalent dose. The CFU count after 28 days of treatment increased 214 
compared to the CFU count at start of treatment. There only was a significant difference in the 215 
imipenem-clavunlaate treated mice (35). 216 
 217 
Meropenem 218 
It has been reported that 300 mg/kg BID meropenem alone, and in combination with 50 mg/kg 219 












tissues in C57BL/6 mice (40). Veziris et al. reported a CFU increase compared to start of the 221 
treatment of meropenem when given as mono-therapy or in combination with clavulanate in a dose 222 
of 100 mg/kg, on CFUs, spleen weights, or lung lesions in Swiss mice (35). Meropenem in a dose of 223 
300 mg/kg in combination with clavulanate, 75 mg/kg thrice-daily given to BALB/c mice showed 224 
marginal reduction in CFU counts in the acute model and no reduction in the chronic model (34). 225 
Meropenem, given subcutaneously 300 mg/kg three times a day, showed a CFU count reduction of 226 
1.7 log in the lungs of TF3157 DHP-1 deficient mice.  (53) 227 
 228 
Ertapenem 229 
In a murine TB model infected with H37Rv, a dose of 100 mg/kg once daily ertapenem as 230 
monotherapye or in combination with clavulanate had neither bactericidal nor bacteriostatic activity 231 
in lungs and spleens of TB-infected mice. Spleen weight and lung lesions remained similar compared 232 
to the untreated group of mice. There was an increase in CFUs compared to the CFUs at the start of 233 
the treatment (35). 234 
Other Carbapenems  235 
An oral dose of 500 mg/kg Faropenem medoxil, given three times daily, gave a reduction of 2 log CFU 236 
count in the lungs of TF3157 DHP-1 deficient mice (53). Neither in vivo nor clinical studies for other 237 
carbapenems as part of a multi-drug regimen against TB were retrieved. 238 
 239 
Clinical studies 240 
Results of the clinical studies reporting on carbapenems are presented in table 3. 241 
 242 
Imipenem 243 
Ten patients were treated with imipenem in combination with two or more other antimicrobial 244 












conversion in these patients (52). A prospective study evaluated 1000 mg/day imipenem/clavulanate 246 
at a dose of once daily in 12 patients, 11 of these patients received linezolid-containing regimens. All 247 
patients showed sputum and culture conversion within 180 days. No adverse events were reported 248 
for imipenem/clavulanate (54). In a large observational study, the clinical outcomes of 84 patients, 249 
treated with 500 mg imipenem/clavulanate four times a day, were compared with results from 168 250 
controls. The study showed that imipenem-containing regimens achieved comparable results 251 
compared to the imipenem sparing regimens, while success rates were similar to major international 252 
MDR-TB cohorts (55).  253 
 254 
Meropenem 255 
A regimen including meropenem-clavulanate given to 18 patients with severe pulmonary XDR-TB led 256 
to sputum culture conversion in 15 patients, of which 10 has successfully completed and five patients 257 
were considered cured according to WHO guidelines. Long-term safety was not a problem in this 258 
study as no adverse events were reported (56-57). The first study, that evaluated efficacy, safety and 259 
tolerability, was a case-control study in 37 patients, who received meropenem/clavulanate as part of 260 
a linezolid based multi-drug regimen. This is the first study that showed an added value of 261 
meropenem/clavulanate in a multi-drug regimen. The meropenem/clavulanate containing regimen 262 
showed a sputum microscopy conversion of 87.5 % and a sputum culture conversion of 83.8%, while 263 
the meropenem/clavulanate sparing regimen showed a sputum microscopy conversion of 56.3% and 264 
a sputum culture conversion of 62.5% after 90 days of treatment (58). In another study, 10 XDR and 265 
pre-XDR female patients were treated with multi-drug regimens and received 266 
meropenem/clavunlanate for 6 months or more. Eight patients achieved sputum conversion after 6 267 
months, while two patients died. (59). Pharmacokinetic parameters of 1 g meropenem/clavulanate 268 
given intravenously over 5 minutes showed a serum peak of 112 mg/ml and a concentration of 28.6 269 
mg*h/L (39). In an observational retrospective cohort-study, efficacy and safety were evaluated in 96 270 












Sputum smear and culture conversion rates were found to be similar (60) In an observational study 272 
comparing therapeutic contribution, such as sputum smear and culture conversion rates and success 273 
rates, of imipenem/clavulanate and meropenem/ clavulanate in a background regimen, suggested 274 
that meropenem/clavulanate can contribute to the efficacy of a regimen in treating M/XDR-TB 275 
patients (11). 276 
 277 
Ertapenem 278 
The first report on clinical experience with ertapenem presented data from five patients who were 279 
treated with an intravenous injection of 1 g ertapenem once daily in a multi-drug regimen. Three of 280 
these patients showed sputum smear and culture conversion; four of five patients had a successful 281 
treatment outcome. Two patients interruped treatment due to an adverse event. These adverse 282 
events were considered unrelated to the study drug (61). In an observational study 18 patients were 283 
treated with 1 g ertapenem once daily; fifteen of these patients had a successful treatment outcome 284 
were cured. Three patients were lost due to follow-up. Three patients stopped ertapenem treatment 285 
due to ertapenem unrelated adverse events. Pharmacokinetic parameters were evaluated in 12 286 
patients, showing a mean peak plasma of 127.5 (range 73.9 - 277.9) mg /L and an AUC of 544.9 287 
(range 390 - 1130) mg*h/L. Based on a MIC of 0.25 mg/ml 11/12 patients reached the target value of 288 
40% Tfree>MIC was exceeded (10). The pharmacokinetic model composed in this study was shown to 289 
adequately predict ertapenem exposure in MDR-TB patients. The Monte Carlo simulation, which had 290 
a time restriction of 0–6 h, showed that the best performing limited sampling strategy was at 1 and 5 291 
h after intravenous injection. (62). In another pharmacokinetic model study using prospective data 292 
from 12 TB patients it was observed that 2 g ertapenem once daily resulted in a more than a dose-293 
proportional increase in AUC compared to once daily 1 g ertapenem. Based on a MIC of 1.0 mg/L, 11 294 














Hugonnet and colleagues first stated that carbapenems have antimycobacterial activity (7). 298 
Subsequently, studies addressing the inactivation mechanism of LDT provided the underlying 299 
evidence to support the hypothesis of activity of carbapenems against M. tuberculosis (14-28). In 300 
spite of this a series of in vitro studies have been carried out, some of which detected an effect and 301 
some of which did not (8,32-50). Only later, was it recognized that these confusing results are 302 
probably explained by the chemical instability of carbapenems, in culture media at the temperatures 303 
typically used in in vitro studies, and many previously published in vitro studies are likely to have 304 
reported falsely high MICs (45). 305 
 306 
Overall the results of the studies identified in this review, which used a variety of experimental 307 
methods to test clinical and laboratory strains of M. tuberculosis for susceptibility to carbapenems, 308 
are consistent. Carbapenems are more active against M. tuberculosis if used in combination with 309 
clavulanate, a BLaC inhibitor. (8,32-50). In line with these in vitro studies the addition of clavulanate 310 
improved the survival rate in mice (35). As the European Medicines Agency (EMA) has accepted and 311 
qualified the in vitro hollow fiber system models as a methodology to define pharmacokinetic and 312 
pharmacodynamic (PK/PD) parameters, these modern in vitro studies can be used to avoid the 313 
problems associated with the chemical instability of these agents in standard agar based MIC testing. 314 
Thus, hollow fiber systems have the potential for dose finding and regimen selection studies on the 315 
use of carbapenems in the treatment of TB (64-65).  316 
Few in vivo studies have been performed due to the short half-life and lower serum concentrations 317 
of carbapenems in mice (35).  318 
 319 
One prospective, two observational and seven retrospective clinical studies to assess effectiveness, 320 
safety and tolerability of three different carbapenems (imipenem, meropenem and ertapenem) have 321 
been performed. Adverse events due to carbapenems were mild, confirming what we know from 322 












only two large retrospective studies with M/XDR-TB patients have been performed with imipenem 324 
(84 patients), and meropenem (96 patients) (11). Meropenem/ clavulanate was suggested to be 325 
more efficient in managing M/XDR-TB (11), however interpretational limitations were mentioned.   326 
 327 
We found no clear evidence to select one particular carbapenem among the different candidate 328 
compounds, when designing an effective M/XDR-TB regimen. Both economical and clinical factors 329 
play a role. Whereas imipenem is the cheaper carbapenem, ertapenem has the potential advantage 330 
that it is only given once daily; and meropenem is by some authors believed to be the most effective 331 
in humans, but no head-to-head comparison studies have confirmed this to date. Therefore, more 332 
clinical evidence and dose optimization substantiated for example by hollow fiber infection studies 333 
are needed to support the repurposing carbapenems for the treatment of M/XDR-TB. 334 
 335 
Clinical studies are hampered by the fact that currently no combination of a carbapenem with 336 
clavulanate is commercially available. Furthermore, clavulanate is not available alone so at present it 337 
is not practically possible to prescribe carbapenem with clavulanate. Therefore, amoxicillin – 338 
clavulanate is often co-administered along with a carbapenem in case the latter is preferred for 339 
treatment. Unfortunately, amoxicillin has gastrointestinal side effects potentially complicating 340 
prolonged treatment. Therefore, combined treatment amoxicillin– clavulanate with a carbapenem is 341 
only an option for TB treatment of complicated cases showing multi- or extensive drug resistance 342 
(42). Although, Gonzalo et al. reported a potential benefit that MIC values drop when amoxicillin is 343 
added to a combination of meropenem and clavulanate. 344 
Due to different procedures, analytical methods and design, the biochemical instability of the drugs 345 
of interest, the short half-live of drugs of interest in mice, diversity in MIC determination and 346 
intolerance in addition to resistance, it was not possible to perform a meta-analysis. While the 347 
observational data are promising, carbapenems can only recommended in case of resistance to 348 












The ideal carbapenem would have the antimycobacterial activity of imipenem, the half-life of 350 
ertapenem and the oral bioavailability of tebipenem-pivoxil. Due to increasing resistance observed in 351 
XDR-TB isolates (66-67) and in MDR-TB patients with resistance to an aminoglycoside, carbapenems 352 
may be a valuable alternative to the current injectable second line drugs. Assessment of intracellular 353 
activity as well as activity against dormant M. tuberculosis by carbapenems is a critical step to further 354 
explore the potential of these repurposed drugs.  355 
As successful treatment outcome for M/XDR-TB is still poor, ranging from 25-50% (1) an 356 
improvement of the current treatment is urgently needed. An individual data meta-analysis among 357 
12,030 individual patients from 50 studies showed a significantly better treatment outcome for 358 
patients who received carbapenems compared to other drugs traditionally used for treatment of 359 
MDR-TB. (68). Since there is a need for new or repurposed drugs for the treatment of M/XDR-TB, 360 
phase II/ III clinical trials are urgently needed for carbapenems to further evaluate their potential. 361 
Long term safety and activity against M. tuberculosis are supported by observational data and several 362 
studies (41,50,69). A phase II prospective randomized controlled study evaluating a carbapenem plus 363 
a BLaC inhibitor on top of an optimized background regimen versus standard of care would be an 364 
appropriate strategy to test the potential benefits of carbapenems for M/XDR-TB treatment. 365 
 366 
Conclusion 367 
Now the variable results of in vitro studies have been explained and the activity of carbapenems in 368 
the presence of a BLaC inhibitor is established, these drugs should be further developed for the 369 
treatment of multi- and extensive drug resistant M. tuberculosis. Ultimately, a well-designed phase 2 370 
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Figure 1: Flow chart 639 
Table 1: Results of the in vitro studies reporting on carbapenems 640 
N: number of strains, MIC: Minimal inhibitory concentration (mg/L), MIC50: Minimal inhibitory 641 
concentration required to inhibit growth of 50% of the organisms, MIC90: Minimal inhibitory 642 
concentration required to inhibit growth of 90% of the organisms, CLV: clavulanate (mg/L) , MBC99: 643 
minimal bactericidal concentration that kills 99% of replication culture (mg/L), CFU: colony forming 644 
units (Log/(CFU/ml)) 645 
Table 2: Results of the in vivo studies reporting on carbapenems 646 
MIC: Minimal inhibitory concentration (mg/L) , CLV: clavulanate (mg/L) , MBC: minimal bactericidal 647 
concetration (mg/L), CFU: colony forming units. qd: once a day, bid: twice a day, tid: three times a 648 
dat, qid: four times a day, ND: not described. 649 
 650 
Table 3: Results of the in human studies reporting on carbapenems 651 
qd: once a day, bid: twice a day, tid: three times a dat, qid: four times a day. PK: pharmacokinetic, 652 
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              2 log 
Solapure et al 
(34) 









    0.5 
1 
2 
    4 (5 mg/ml) 
2 ( 
4   
Srivastava et al 
(45) 
H37Ra 1 Resazurin 
microdilution assay 
Ertapenem Clavunalate 
0.6             2.38 log10 
Veziris et al 
(35) 







16     
1 
1 












Table 2: Results of the in vivo studies reporting on carbapenems 
First author 
(ref). Strain Mice Infection Drug Dose 
Infection 
model Treatment End-point Organs CFU reduction 
Surviva
l rate CFU/ clv 
Chambers 
et al (52) 
H37Rv CD-1 Female 
mice 
subcutaneously Imipenem Bid 100 
mg/kg 
ND 28 days CFU count, 
Survival 
rate 
Spleen, lungs 1.8 log 65% ND 
Dhar et al 
(49) 
H37Rv adult C57BL/6J 
mice 
intratracheal Faropenem 500 mg/kg acute TB 8 days CFU count Lungs reduction of 








2 weeks CFU count Spleen, lungs 
1 log  ND 1 log 
    New zealand 
white rabbits 
intravenous bolus Meropenem 75 mg/kg 
125 mg/kg 
ND ND PK data ND ND ND ND 
Kaushik et 
al (51) 














Rullas et al 
(53) 
 
























4 weeks CFU count lungs 
no reduction ND 
no 
reduction 
Veziris et al 
(35) 










28 days CFU count, 
Survival 
rate 
























































n due AE 






retrospective Imipenem 1 g oc 12 No 12/12 12/12 7/12 0/12 0/12 
Chambers et al 
(52) 
2005 USA 
ND Prospective Imipenem 1 g bid 10 No ND 8/10 7/10 ND ND 










m 1 g tid 37 No 28/32 31/37 ND 5/37 2/5 









2 g tid (then 
bid) 18 No 16/18 16/18 15/18 0/18 0/18 







2 g tid (then 
1 g tid) 10 No ND 8/10 3/6 0/10 ND 







Ertapenem 1 g oc 
18 yes ND 15/18 15/18 2/18 3/18 









Ertapenem 1 g oc 
5 No 3/5 3/5 4/5 0/5 0/5 












1 g tid (2g 
tid) 



















Imipenem 500 mg qid 
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